Anqi Lin, Junyi Shen, Zhenyu Xie, Quan Cheng, Jian Zhang, Peng Luo
{"title":"儿童免疫检查点抑制剂相关不良事件的综合图谱：从现实世界的药物警戒数据到机制见解","authors":"Anqi Lin, Junyi Shen, Zhenyu Xie, Quan Cheng, Jian Zhang, Peng Luo","doi":"10.1002/ctd2.70086","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Immune checkpoint inhibitors (ICIs) are widely used in childhood cancer, posing challenges with associated ICIs-related adverse events (irAEs). This study focuses on pediatric irAEs and explores underlying mechanisms.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data on ICI-related adverse reactions were gathered from two sources: VigiBase database (1967–2023) and the FDA Adverse Event Reporting System (FAERS) database (2013–2022). Disproportionality analysis (Reporting odds ratio, proportional reporting ratio, information component) compared pediatric and adult cancer patients using ICIs. Integration with the Gene Expression Omnibus (GEO) database explored potential biological mechanisms.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified four categories of pediatric irAEs in the VigiBase and FAERS databases, including cytokine release syndrome (ROR<sub>VigiBase</sub> = 17.05; ROR<sub>FAERS</sub> = 14.17), acute respiratory distress syndrome (ROR<sub>VigiBase</sub> = 10.26; ROR<sub>FAERS</sub> = 12.39), seizure (ROR<sub>VigiBase</sub> = 7.18; ROR<sub>FAERS</sub> = 10.63), and febrile neutropenia (FN) (ROR<sub>VigiBase</sub> = 3.01; ROR<sub>FAERS</sub> = 4.84). The development of irAEs in pediatric patients potentially involves various pathways: immune activation, inflammatory imbalance, pathogen recognition systems, decreased inhibitory synapses, altered E/I ratios, and CNS abnormalities.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study explores pediatric irAEs, revealing potential mechanisms and stressing tailored prevention for young cancer patients on ICIs, providing theoretical insights for better management.</p>\n </section>\n </div>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"5 5","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.70086","citationCount":"0","resultStr":"{\"title\":\"A comprehensive atlas of pediatric immune checkpoint inhibitors-related adverse events: From real-world pharmacovigilance data to mechanistic insights\",\"authors\":\"Anqi Lin, Junyi Shen, Zhenyu Xie, Quan Cheng, Jian Zhang, Peng Luo\",\"doi\":\"10.1002/ctd2.70086\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Immune checkpoint inhibitors (ICIs) are widely used in childhood cancer, posing challenges with associated ICIs-related adverse events (irAEs). This study focuses on pediatric irAEs and explores underlying mechanisms.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Data on ICI-related adverse reactions were gathered from two sources: VigiBase database (1967–2023) and the FDA Adverse Event Reporting System (FAERS) database (2013–2022). Disproportionality analysis (Reporting odds ratio, proportional reporting ratio, information component) compared pediatric and adult cancer patients using ICIs. Integration with the Gene Expression Omnibus (GEO) database explored potential biological mechanisms.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We identified four categories of pediatric irAEs in the VigiBase and FAERS databases, including cytokine release syndrome (ROR<sub>VigiBase</sub> = 17.05; ROR<sub>FAERS</sub> = 14.17), acute respiratory distress syndrome (ROR<sub>VigiBase</sub> = 10.26; ROR<sub>FAERS</sub> = 12.39), seizure (ROR<sub>VigiBase</sub> = 7.18; ROR<sub>FAERS</sub> = 10.63), and febrile neutropenia (FN) (ROR<sub>VigiBase</sub> = 3.01; ROR<sub>FAERS</sub> = 4.84). The development of irAEs in pediatric patients potentially involves various pathways: immune activation, inflammatory imbalance, pathogen recognition systems, decreased inhibitory synapses, altered E/I ratios, and CNS abnormalities.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This study explores pediatric irAEs, revealing potential mechanisms and stressing tailored prevention for young cancer patients on ICIs, providing theoretical insights for better management.</p>\\n </section>\\n </div>\",\"PeriodicalId\":72605,\"journal\":{\"name\":\"Clinical and translational discovery\",\"volume\":\"5 5\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.70086\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and translational discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.70086\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and translational discovery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.70086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A comprehensive atlas of pediatric immune checkpoint inhibitors-related adverse events: From real-world pharmacovigilance data to mechanistic insights
Background
Immune checkpoint inhibitors (ICIs) are widely used in childhood cancer, posing challenges with associated ICIs-related adverse events (irAEs). This study focuses on pediatric irAEs and explores underlying mechanisms.
Methods
Data on ICI-related adverse reactions were gathered from two sources: VigiBase database (1967–2023) and the FDA Adverse Event Reporting System (FAERS) database (2013–2022). Disproportionality analysis (Reporting odds ratio, proportional reporting ratio, information component) compared pediatric and adult cancer patients using ICIs. Integration with the Gene Expression Omnibus (GEO) database explored potential biological mechanisms.
Results
We identified four categories of pediatric irAEs in the VigiBase and FAERS databases, including cytokine release syndrome (RORVigiBase = 17.05; RORFAERS = 14.17), acute respiratory distress syndrome (RORVigiBase = 10.26; RORFAERS = 12.39), seizure (RORVigiBase = 7.18; RORFAERS = 10.63), and febrile neutropenia (FN) (RORVigiBase = 3.01; RORFAERS = 4.84). The development of irAEs in pediatric patients potentially involves various pathways: immune activation, inflammatory imbalance, pathogen recognition systems, decreased inhibitory synapses, altered E/I ratios, and CNS abnormalities.
Conclusions
This study explores pediatric irAEs, revealing potential mechanisms and stressing tailored prevention for young cancer patients on ICIs, providing theoretical insights for better management.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
